AbbVie’s Humira is still on top, but biosimilars are chipping away at its dominance

The share of AbbVie’s brand-name version of Humira has dropped to 82% of the total market, 13% less than in March, according to a Samsung …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Soaring MSOs Lead Cannabis Stocks Higher in January

As we described in a previous article, the Global Cannabis Stock Index extended the bounce from November after the huge October loss, rallying 8.1% in December. That index was

February 1, 2024

GSK offers glimpse at RSV vaccine in at-risk younger adults before ACIP meeting

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 25, 2024

FDA’s latest reorganization puts a new emphasis on its investigations

Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us

November 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.